Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination.

IF 1.5 4区 医学 Q2 PEDIATRICS
Sarah O'Dor, Celia Adams, Jessica Gavin, Julia S Zagaroli, Elliott Carlisle, Olivia M Downer, Kyle A Williams, Erin E Masterson
{"title":"Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination.","authors":"Sarah O'Dor, Celia Adams, Jessica Gavin, Julia S Zagaroli, Elliott Carlisle, Olivia M Downer, Kyle A Williams, Erin E Masterson","doi":"10.1089/cap.2024.0129","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> SARS-CoV-2 (COVID-19) infection has been implicated in the onset of neuropsychiatric symptoms in adults and children. While outcomes of COVID-19 infection and vaccination have been tracked in the general pediatric population, little is known of their impact on children with preexisting neuropsychiatric syndromes, including pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). The aim of this study is to understand the prevalence and severity of COVID-19 symptoms and PANS/PANDAS symptoms following COVID-19 infection or vaccination in children with PANS/PANDAS. <b><i>Methods:</i></b> We analyzed retrospective COVID-19 survey data from caregivers of youth with PANS/PANDAS at Massachusetts General Hospital (MGH; <i>n</i> = 57) and the International PANS Registry (IPR; <i>n</i> = 478). Surveys were conducted online between late 2021 and early 2022 to collect COVID-19 infection and vaccination histories, side effects, and changes in PANS/PANDAS symptoms. Descriptive results are reported, stratified by case and sibling groups within the IPR sample. <b><i>Results:</i></b> Among patients with test-confirmed COVID-19 (MGH: <i>n</i> = 20, IPR: <i>n</i> = 65 cases, <i>n</i> = 16 siblings), mild/minor COVID-19 symptoms were common (62-75%). All patients with preexisting PANS/PANDAS-related symptoms at the time of COVID-19 infection experienced an exacerbation of PANS/PANDAS symptoms, while remitted patients did not report any PANS/PANDAS symptoms. Following the first COVID-19 vaccine dose (MGH: <i>n</i> = 45, IPR: <i>n</i> = 150 cases, <i>n</i> = 44 siblings), fatigue was the predominant side effect (30-56%). Most patients did not report new (59-81%) or worsened (71-82%) PANS symptoms post-vaccination, irrespective of symptomatic status at vaccination. Vaccine hesitancy often stemmed from concerns that the vaccination would cause an exacerbation of PANS/PANDAS symptoms. <b><i>Conclusions:</i></b> In two samples of children with PANS/PANDAS, symptoms of COVID-19 following infection and vaccination were common and generally mild to moderate. Children experiencing PANS/PANDAS symptoms at the time of COVID-19 infection experienced an increase in PANS/PANDAS symptom severity.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of child and adolescent psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cap.2024.0129","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: SARS-CoV-2 (COVID-19) infection has been implicated in the onset of neuropsychiatric symptoms in adults and children. While outcomes of COVID-19 infection and vaccination have been tracked in the general pediatric population, little is known of their impact on children with preexisting neuropsychiatric syndromes, including pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). The aim of this study is to understand the prevalence and severity of COVID-19 symptoms and PANS/PANDAS symptoms following COVID-19 infection or vaccination in children with PANS/PANDAS. Methods: We analyzed retrospective COVID-19 survey data from caregivers of youth with PANS/PANDAS at Massachusetts General Hospital (MGH; n = 57) and the International PANS Registry (IPR; n = 478). Surveys were conducted online between late 2021 and early 2022 to collect COVID-19 infection and vaccination histories, side effects, and changes in PANS/PANDAS symptoms. Descriptive results are reported, stratified by case and sibling groups within the IPR sample. Results: Among patients with test-confirmed COVID-19 (MGH: n = 20, IPR: n = 65 cases, n = 16 siblings), mild/minor COVID-19 symptoms were common (62-75%). All patients with preexisting PANS/PANDAS-related symptoms at the time of COVID-19 infection experienced an exacerbation of PANS/PANDAS symptoms, while remitted patients did not report any PANS/PANDAS symptoms. Following the first COVID-19 vaccine dose (MGH: n = 45, IPR: n = 150 cases, n = 44 siblings), fatigue was the predominant side effect (30-56%). Most patients did not report new (59-81%) or worsened (71-82%) PANS symptoms post-vaccination, irrespective of symptomatic status at vaccination. Vaccine hesitancy often stemmed from concerns that the vaccination would cause an exacerbation of PANS/PANDAS symptoms. Conclusions: In two samples of children with PANS/PANDAS, symptoms of COVID-19 following infection and vaccination were common and generally mild to moderate. Children experiencing PANS/PANDAS symptoms at the time of COVID-19 infection experienced an increase in PANS/PANDAS symptom severity.

小儿神经精神综合征:COVID-19感染和疫苗接种的最新进展。
SARS-CoV-2 (COVID-19)感染与成人和儿童神经精神症状的发病有关。虽然在一般儿科人群中追踪了COVID-19感染和疫苗接种的结果,但对其对先前存在神经精神综合征的儿童的影响知之甚少,包括儿科急性发作神经精神综合征(PANS)和与链球菌感染相关的儿科自身免疫性神经精神疾病(PANDAS)。本研究的目的是了解pan /PANDAS患儿在COVID-19感染或接种疫苗后的COVID-19症状和pan /PANDAS症状的患病率和严重程度。方法:分析马萨诸塞州总医院(MGH) pan /PANDAS青少年护理人员的回顾性COVID-19调查数据;n = 57)和国际PANS注册处(IPR;N = 478)。在2021年底至2022年初期间进行了在线调查,以收集COVID-19感染和疫苗接种史、副作用以及PANS/PANDAS症状的变化。报告了描述性结果,并按IPR样本中的病例和兄弟姐妹组分层。结果:在新冠肺炎检测确诊患者中(MGH: n = 20例,IPR: n = 65例,兄弟姐妹n = 16例),轻/轻微症状较常见(62-75%)。所有在COVID-19感染时已存在pan /PANDAS相关症状的患者均出现了pan /PANDAS症状加重,而缓解的患者未报告任何pan /PANDAS症状。第一次接种COVID-19疫苗(MGH: n = 45例,IPR: n = 150例,兄弟姐妹n = 44例)后,疲劳是主要副作用(30-56%)。大多数患者在接种疫苗后没有报告新的(59-81%)或恶化的(71-82%)pan症状,无论接种疫苗时的症状状况如何。疫苗犹豫往往源于担心接种疫苗会导致pan /PANDAS症状恶化。结论:在2例pan /PANDAS患儿样本中,感染和接种疫苗后出现的COVID-19症状较为常见,一般为轻至中度。在感染COVID-19时出现pan /PANDAS症状的儿童pan /PANDAS症状严重程度增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.60
自引率
5.30%
发文量
61
审稿时长
>12 weeks
期刊介绍: Journal of Child and Adolescent Psychopharmacology (JCAP) is the premier peer-reviewed journal covering the clinical aspects of treating this patient population with psychotropic medications including side effects and interactions, standard doses, and research on new and existing medications. The Journal includes information on related areas of medical sciences such as advances in developmental pharmacokinetics, developmental neuroscience, metabolism, nutrition, molecular genetics, and more. Journal of Child and Adolescent Psychopharmacology coverage includes: New drugs and treatment strategies including the use of psycho-stimulants, selective serotonin reuptake inhibitors, mood stabilizers, and atypical antipsychotics New developments in the diagnosis and treatment of ADHD, anxiety disorders, schizophrenia, autism spectrum disorders, bipolar disorder, eating disorders, along with other disorders Reports of common and rare Treatment Emergent Adverse Events (TEAEs) including: hyperprolactinemia, galactorrhea, weight gain/loss, metabolic syndrome, dyslipidemia, switching phenomena, sudden death, and the potential increase of suicide. Outcomes research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信